FOR IMMEDIATE RELEASE
 
CONTACT:
Natasha Joseph

Merial
(678) 638-aaep-200690
natasha.joseph@merial.com

Michele Egan
Merial
(678) 638-3524
michele.egan@merial.com
EQUIOXX¨ (firocoxib) Sponsors
International Society of Equine Locomotor Pathology
Supports veterinary education in the field of equine lameness

DULUTH, GA – January 20, 2010 – EQUIOXX¨ (firocoxib) is now a corporate sponsor of the International Society of Equine Locomotor Pathology (ISELP) – a partnership that helps advance equine veterinarians’ knowledge of equine pain management.

“We are proud to support an organization that has done so much to enhance our understanding of equine lameness,” says Hoyt Cheramie, DVM, MS, manager, Equine Veterinary Services, Merial Limited. “We at Merial want to continue advancing the field by supporting ISELP.”

EQUIOXX is the first nontopical nonsteroidal anti-inflammatory drug (NSAID) approved in the past 17 years. With once-daily dosing, EQUIOXX provides 24 hours of relief from the pain and inflammation associated with equine osteoarthritis and is approved for use up to 14 days.1,2 As a corporate partner, EQUIOXX helps support ISELP’s ongoing continuing education programs for veterinarians. Each year, ISELP holds five seminars across the United States and in Europe. More than 200 veterinarians are members of the organiza